Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Cash Equivalents | 1,063.22 | 0.04 | 230.06 | 199.07 |
Short Term Investments | 943.36 | 1,619.18 | 2,544.69 | 732.00 |
Cashand Short Term Investments | 2,006.58 | 1,654.12 | 2,830.88 | 1,137.19 |
Accounts Receivable- Trade Net | 222.06 | 206.45 | 212.88 | 223.11 |
Total Receivables Net | 222.06 | 341.93 | 305.17 | 297.49 |
Total Inventory | 525.05 | 459.97 | 534.70 | 546.70 |
Other Current Assets Total | 44.73 | 23.29 | 23.37 | 206.62 |
Total Current Assets | 2,798.42 | 2,494.26 | 3,708.03 | 2,202.64 |
Property/ Plant/ Equipment Total- Net | 310.73 | 315.12 | 325.45 | 355.41 |
Intangibles Net | 23.55 | 34.09 | 34.50 | 43.36 |
Long Term Investments | 11.14 | 1.06 | 1.21 | 1.35 |
Note Receivable- Long Term | 213.64 | 302.21 | 407.07 | 349.56 |
Other Long Term Assets Total | 199.14 | 179.84 | 157.02 | 162.32 |
Total Assets | 3,556.62 | 3,326.58 | 4,633.28 | 3,114.65 |
Accounts Payable | 625.41 | 427.79 | 570.55 | 466.13 |
Current Portof LT Debt/ Capital Leases | 12.20 | 12.08 | 12.45 | 14.35 |
Other Currentliabilities Total | 887.34 | 791.79 | 1,012.35 | 739.62 |
Total Current Liabilities | 1,524.95 | 1,326.37 | 1,698.43 | 1,354.58 |
Capital Lease Obligations | 6.47 | 3.46 | 7.62 | 20.25 |
Total Long Term Debt | 6.47 | 3.46 | 7.62 | 20.25 |
Total Debt | 18.67 | 15.54 | 20.08 | 34.63 |
Other Liabilities Total | 247.56 | 255.49 | 264.27 | 261.56 |
Total Liabilities | 1,778.98 | 1,585.31 | 1,970.32 | 1,636.39 |
Common Stock Total | 169.41 | 169.41 | 169.41 | 169.41 |
Retained Earnings( Accumulated Deficit) | 1,608.23 | 1,571.87 | 2,493.55 | 1,308.85 |
Total Equity | 1,777.64 | 1,741.27 | 2,662.96 | 1,478.26 |
Total Liabilities Shareholders' Equity | 3,556.62 | 3,326.58 | 4,633.28 | 3,114.65 |
Total Common Shares Outstanding | 16.94 | 16.94 | 16.94 | 16.94 |
Tangible Book Valueper Share Common Eq | 103.54 | 100.77 | 155.16 | 84.70 |
Cash | - | 34.90 | 56.13 | 206.12 |
Prepaid Expenses | - | 14.96 | 13.93 | 14.65 |
Property/ Plant/ Equipment Total- Gross | - | 570.66 | 548.10 | 540.42 |
Accumulated Depreciation Total | - | -255.54 | -222.66 | -185.01 |
Accrued Expenses | - | 94.71 | 103.08 | 134.45 |
Notes Payable/ Short Term Debt | - | 0.00 | 0.00 | 0.02 |
Glaxosmithkline Pharmaceuticals Dividend Glaxosmithkline Pharmaceuticals Bonus Glaxosmithkline Pharmaceuticals News Glaxosmithkline Pharmaceuticals AGM Glaxosmithkline Pharmaceuticals Rights Glaxosmithkline Pharmaceuticals Splits Glaxosmithkline Pharmaceuticals Board Meetings Glaxosmithkline Pharmaceuticals Key Metrics Glaxosmithkline Pharmaceuticals Shareholdings Glaxosmithkline Pharmaceuticals Profit Loss Glaxosmithkline Pharmaceuticals Cashflow Glaxosmithkline Pharmaceuticals Q1 Results Glaxosmithkline Pharmaceuticals Q2 Results Glaxosmithkline Pharmaceuticals Q3 Results Glaxosmithkline Pharmaceuticals Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks